Number of the records: 1  

A novel class of cardioprotective small-molecule PTP inhibitors

  1. 1.
    SYSNO ASEP0524241
    Document TypeJ - Journal Article
    R&D Document TypeJournal Article
    Subsidiary JČlánek ve WOS
    TitleA novel class of cardioprotective small-molecule PTP inhibitors
    Author(s) Antonucci, S. (IT)
    Di Sante, M. (IT)
    Sileikyte, J. (US)
    Deveraux, J. (US)
    Bauer, T. (US)
    Bround, M. J. (US)
    Menabo, R. (IT)
    Paillard, M. (FR)
    Alánová, Petra (FGU-C) RID, ORCID
    Carraro, M. (IT)
    Ovize, M. (FR)
    Molkentin, J. D. (US)
    Cohen, M. (US)
    Forte, M. A. (US)
    Bernardi, P. (IT)
    Di Lisa, F. (IT)
    Murphy, E. (US)
    Article number104548
    Source TitlePharmacological Research. - : Elsevier - ISSN 1043-6618
    Roč. 151, Jan (2020)
    Number of pages12 s.
    Languageeng - English
    CountryGB - United Kingdom
    Keywordspermeability transition ; mitochondria ; cardiomyocytes ; cardioprotection ; ischemia ; reperfusion
    Subject RIVFA - Cardiovascular Diseases incl. Cardiotharic Surgery
    OECD categoryCardiac and Cardiovascular systems
    Method of publishingLimited access
    Institutional supportFGU-C - RVO:67985823
    UT WOS000527002000005
    EID SCOPUS85075501209
    DOI10.1016/j.phrs.2019.104548
    AnnotationIschemia/reperfusion (I/R) injury is mediated in large part by opening of the mitochondrial permeability transition pore (PTP). Consequently, inhibitors of the PTP hold great promise for the treatment of a variety of cardiovascular disorders. At present, PTP inhibition is obtained only through the use of drugs (e.g. cyclosporine A, CsA) targeting cyclophilin D (CyPD) which is a key modulator, but not a structural component of the PTP. This limitation might explain controversial findings in clinical studies. Therefore, we investigated the protective effects against I/R injury of small-molecule inhibitors of the PTP (63 and TR002) that do not target CyPD. Both compounds exhibited a dose-dependent inhibition of PTP opening in isolated mitochondria and were more potent than CsA. Notably, PTP inhibition was observed also in mitochondria devoid of CyPD. Compounds 63 and TR002 prevented PTP opening and mitochondrial depolarization induced by Ca2+ overload and by reactive oxygen species in neonatal rat ventricular myocytes (NRVMs). Remarkably, both compounds prevented cell death, contractile dysfunction and sarcomeric derangement induced by anoxia/reoxygenation injury in NRVMs at sub-micromolar concentrations, and were more potent than CsA. Cardioprotection was observed also in adult mouse ventricular myocytes and human iPSc-derived cardiomyocytes, as well as ex vivo in perfused hearts. Thus, this study demonstrates that 63 and TR002 represent novel cardioprotective agents that inhibit PTP opening independent of CyPD targeting.
    WorkplaceInstitute of Physiology
    ContactLucie Trajhanová, lucie.trajhanova@fgu.cas.cz, Tel.: 241 062 400
    Year of Publishing2021
    Electronic addresshttps://doi.org/10.1016/j.phrs.2019.104548
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.